SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,663,443 | +172.0% | 129,419 | +521.5% | 0.02% | +162.5% |
| Q2 2023 | $979,097 | +72.6% | 20,823 | +40.0% | 0.01% | +60.0% |
| Q4 2022 | $567,218 | +57.6% | 14,872 | +61.6% | 0.01% | +66.7% |
| Q3 2022 | $360,000 | -34.8% | 9,204 | -44.8% | 0.00% | -40.0% |
| Q1 2022 | $552,000 | -51.9% | 16,680 | +8.8% | 0.01% | -64.3% |
| Q1 2021 | $1,147,000 | -31.2% | 15,333 | -61.8% | 0.01% | -36.4% |
| Q2 2020 | $1,668,000 | +658.2% | 40,100 | +422.9% | 0.02% | +57.1% |
| Q1 2020 | $220,000 | -14.4% | 7,669 | +115.5% | 0.01% | +133.3% |
| Q4 2019 | $257,000 | -88.8% | 3,558 | -78.3% | 0.01% | -91.2% |
| Q3 2019 | $2,300,000 | +83.0% | 16,400 | +84.3% | 0.07% | +21.4% |
| Q3 2018 | $1,257,000 | +83.8% | 8,900 | +3.7% | 0.06% | -21.1% |
| Q2 2017 | $684,000 | -51.4% | 8,586 | -71.9% | 0.07% | -70.3% |
| Q3 2016 | $1,408,000 | +367.8% | 30,567 | +205.7% | 0.24% | +256.7% |
| Q2 2016 | $301,000 | -17.8% | 10,000 | -12.4% | 0.07% | -55.0% |
| Q1 2016 | $366,000 | – | 11,419 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |